Clinical Feed

Out-of-Pocket Cost of Gene Therapies Among Insured Patients

This cross-sectional study evaluates insurance and patient spending for the spinal muscular atrophy medications nusinersen, onasemnogene abeparvovec-xioi, and risdiplam from 2021 through 2022.

Published: 13 Apr 2026, 12:00 am (UTC)
Updated: 13 Apr 2026, 12:00 am (UTC)
Specialty: Research Highlights
Source: JAMA Pediatrics

GIST

This cross-sectional study evaluates insurance and patient spending for the spinal muscular atrophy medications nusinersen, onasemnogene abeparvovec-xioi, and risdiplam from 2021 through 2022.

Clinical Editorial

This cross-sectional study evaluates insurance and patient spending for the spinal muscular atrophy medications nusinersen, onasemnogene abeparvovec-xioi, and risdiplam from 2021 through 2022.

Original source: https://jamanetwork.com/journals/jamapediatrics/fullarticle/2847696